Univercells S.A.. (12/17/20). "Press Release: Univercells Holding Raises €70 Million in Series C Financing". Brussels.

	Organisation	Univercells S.A.
	Group	Univercells (Group)
	Organisation 2	Korea Investment Partners (KIP)
	Product	contract manufacturing (biologicals)
	Product 2	venture capital
	Index term	Univercells–SEVERAL: investment, 202009 financing round Series C first closing €50m led by Adjuvant Capital + SFPI + SRIW
	Index term 2	Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al
	Person	Bultot, Hugues (Univercells 2013– CEO + Co-Founder)

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics.

Univercells SA recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed, was led by institutional commitments from international funds including Adjuvant Capital and Belgian public investors SFPI (federal), SRIW (Walloon Region). The second close brings in new international investors the Soros Economic Development Fund and Farallon Capital Management another Fund from Korea Investment Partners (KIP Bio Global Fund) and a new Belgian Fund (TheClubDeal Fund).

Investment proceeds will support establishing GMP capabilities at two sites in Jumet, one dedicated to addressing manufacturing bottlenecks for pandemics, alongside new product and platform development to address key global health needs. The financing will also develop Univercells’ capacity to support distributed manufacturing and supply of biologics.

Created to make biologics available and affordable to all, Univercells is delivering on a global mission from Belgian roots. We are delighted to have further expanded the circle of shareholders to include organizations with new skills and networks to support our scale and success. Since April 2020, Univercells SA is structured as an entrepreneurial holding company with multiple affiliates – Univercells Technologies launched in February 2020 with the support of private equity fund KKR, to expand the supply of manufacturing solutions for gene therapies. A second Univercells company, Exothera, delivers bespoke process optimization and GMP clinical and commercial production of viral vectors in our Belgian sites. More Univercells’ companies are expected to formally launch in 2021.

“After the first Series-C closing of €50M, 3 months ago, I am delighted to complete this financing round with an additional €20M, bringing the funds raised this year to a total of 120€M at the level of our organization. It will help our teams to perform and accelerate the developments to achieve our global health challenges” says Hugues Bultot, CEO of Univercells.

Record changed: 2021-01-07